arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Cardiff Oncology, Inc.

CRDF
$1.33 0.00 (-0.37%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
108 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

Cardiff Oncology, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $91.0M
Dividend Yield —
Revenue Growth -14.0% ↗
Op. Margin None
ROIC -28.6% ↗
FCF / Share $-0.17 ↗
Trailing P/E —
Price / Book 3.4x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

108-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$104.00K
↓ -14.0% —
Net Income Profit after all expenses
$-12.35M
↑ +8.1% —
FCF / Share Free cash flow per share
$-0.17
↑ +4.3% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
8
Cash Quality →
56

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 27 years · 108 quarters